Stock listing
NASDAQ:CNTX Context Therapeutics Inc. Stock
Home listing (NASDAQ) of Context Therapeutics Inc.
Follow Context Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CNTX
$0.16 USD -0.01 (-3.8%)
Close on Nov 20, 2026
- Day range
- $0.158 – $0.175 USDNov 20, 2026
- Volume
- 1.11M sharesNov 20, 2026
- Market cap
- $14.70M USDAt the close on Nov 20, 2026 · price × 91.88M shares outstanding
- 52-week range
- $0.153 – $3.62 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $440,840 USDMedian day 1.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CNTX · Home | $0.16 USD | -0.006 (-3.8%) | 1,113,620 | $0.161 | $0.175 | $0.158 | $0.166 | Close on Nov 20, 2026 |
| Frankfurt:6K9 | €0.13 EUR | -0.007 (-5.1%) | — | €0.093 | €0.13 | €0.093 | €0.137 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CNTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.16 | -0.006 | -3.8% | $0.161 | $0.175 | $0.158 | 1,113,620 | |
| $0.166 | -0.005 | -2.7% | $0.171 | $0.176 | $0.158 | 1,243,549 | |
| $0.171 | +0.005 | +3.1% | $0.164 | $0.182 | $0.153 | 2,035,575 | |
| $0.166 | -0.015 | -8.2% | $0.18 | $0.188 | $0.158 | 2,872,738 | |
| $0.181 | -0.017 | -8.7% | $0.20 | $0.207 | $0.18 | 933,085 | |
| $0.198 | -0.018 | -8.4% | $0.214 | $0.214 | $0.196 | 528,687 | |
| $0.216 | +0.029 | +15.6% | $0.193 | $0.216 | $0.186 | 1,350,719 | |
| $0.187 | -0.013 | -6.6% | $0.20 | $0.201 | $0.186 | 721,882 | |
| $0.20 | +0.007 | +3.5% | $0.196 | $0.205 | $0.19 | 765,706 | |
| $0.194 | +0.006 | +3.0% | $0.192 | $0.204 | $0.18 | 1,313,308 | |
| $0.188 | -0.016 | -7.7% | $0.21 | $0.21 | $0.186 | 1,158,398 | |
| $0.204 | +0.009 | +4.9% | $0.203 | $0.21 | $0.199 | 8,240,061 | |
| $0.194 | -0.008 | -4.0% | $0.205 | $0.21 | $0.191 | 981,463 | |
| $0.202 | +0.013 | +6.8% | $0.19 | $0.213 | $0.189 | 1,291,596 | |
| $0.189 | -0.013 | -6.2% | $0.203 | $0.203 | $0.189 | 1,012,585 | |
| $0.202 | -0.01 | -4.5% | $0.211 | $0.215 | $0.20 | 1,308,370 | |
| $0.211 | -0.023 | -10.0% | $0.232 | $0.238 | $0.211 | 1,526,506 | |
| $0.235 | -0.005 | -2.2% | $0.232 | $0.242 | $0.22 | 1,810,190 | |
| $0.24 | +0.001 | +0.4% | $0.239 | $0.247 | $0.229 | 580,331 | |
| $0.239 | +0.003 | +1.3% | $0.228 | $0.24 | $0.215 | 1,484,900 | |
| $0.236 | +0.005 | +2.2% | $0.234 | $0.236 | $0.217 | 1,587,100 | |
| $0.231 | -0.013 | -5.3% | $0.248 | $0.248 | $0.223 | 1,165,300 | |
| $0.244 | +0.006 | +2.5% | $0.238 | $0.253 | $0.228 | 724,400 | |
| $0.238 | -0.006 | -2.5% | $0.243 | $0.267 | $0.23 | 843,400 | |
| $0.244 | +0.003 | +1.2% | $0.258 | $0.27 | $0.222 | 2,235,700 | |
| $0.241 | -0.015 | -5.9% | $0.252 | $0.273 | $0.236 | 1,337,400 | |
| $0.256 | -0.019 | -6.9% | $0.272 | $0.272 | $0.25 | 960,600 | |
| $0.275 | -0.03 | -9.8% | $0.301 | $0.306 | $0.27 | 1,253,900 | |
| $0.305 | +0.001 | +0.3% | $0.294 | $0.308 | $0.29 | 503,300 | |
| $0.304 | +0.005 | +1.7% | $0.30 | $0.31 | $0.298 | 588,700 | |
| $0.299 | -0.014 | -4.5% | $0.311 | $0.317 | $0.295 | 916,600 | |
| $0.313 | -0.009 | -2.8% | $0.316 | $0.323 | $0.311 | 464,200 | |
| $0.322 | -0.015 | -4.5% | $0.339 | $0.362 | $0.318 | 898,700 | |
| $0.337 | +0.027 | +8.7% | $0.31 | $0.34 | $0.31 | 1,001,300 | |
| $0.31 | -0.004 | -1.3% | $0.312 | $0.317 | $0.303 | 329,200 | |
| $0.314 | +0.014 | +4.7% | $0.309 | $0.32 | $0.299 | 1,138,300 | |
| $0.30 | -0.019 | -6.0% | $0.331 | $0.331 | $0.297 | 1,192,700 | |
| $0.319 | -0.007 | -2.1% | $0.323 | $0.332 | $0.312 | 849,400 | |
| $0.326 | -0.02 | -5.8% | $0.349 | $0.349 | $0.321 | 1,551,800 | |
| $0.346 | -0.025 | -6.7% | $0.371 | $0.38 | $0.345 | 1,324,500 | |
| $0.371 | -0.012 | -3.1% | $0.38 | $0.389 | $0.363 | 880,200 | |
| $0.383 | -0.006 | -1.5% | $0.39 | $0.395 | $0.37 | 1,107,100 | |
| $0.389 | +0.014 | +3.7% | $0.389 | $0.397 | $0.37 | 539,000 | |
| $0.375 | +0.007 | +1.9% | $0.379 | $0.388 | $0.364 | 770,200 | |
| $0.368 | -0.015 | -3.9% | $0.389 | $0.40 | $0.368 | 1,209,200 | |
| $0.383 | +0.004 | +1.1% | $0.374 | $0.388 | $0.36 | 1,504,300 | |
| $0.379 | +0.015 | +4.1% | $0.37 | $0.39 | $0.36 | 2,128,000 | |
| $0.364 | +0.013 | +3.7% | $0.364 | $0.383 | $0.351 | 1,375,300 | |
| $0.351 | +0.001 | +0.3% | $0.35 | $0.384 | $0.35 | 2,004,900 | |
| $0.35 | -0.016 | -4.4% | $0.379 | $0.379 | $0.343 | 821,800 | |
| $0.366 | -0.004 | -1.1% | $0.373 | $0.373 | $0.36 | 740,600 | |
| $0.37 | -0.006 | -1.6% | $0.376 | $0.38 | $0.37 | 642,000 | |
| $0.376 | +0.014 | +3.9% | $0.36 | $0.378 | $0.35 | 1,097,500 | |
| $0.362 | -0.001 | -0.3% | $0.365 | $0.37 | $0.347 | 974,900 | |
| $0.363 | 0.00 | 0.0% | $0.371 | $0.375 | $0.355 | 1,441,300 | |
| $0.363 | -0.001 | -0.3% | $0.37 | $0.375 | $0.351 | 1,317,500 | |
| $0.364 | -0.026 | -6.7% | $0.389 | $0.39 | $0.36 | 1,814,700 | |
| $0.39 | +0.006 | +1.6% | $0.385 | $0.399 | $0.375 | 1,280,700 | |
| $0.384 | -0.032 | -7.7% | $0.41 | $0.423 | $0.381 | 3,038,000 | |
| $0.416 | -0.008 | -1.9% | $0.429 | $0.437 | $0.411 | 1,131,900 | |
| $0.424 | -0.011 | -2.5% | $0.429 | $0.439 | $0.417 | 1,029,300 | |
| $0.435 | -0.03 | -6.5% | $0.47 | $0.475 | $0.397 | 8,170,500 | |
| $0.465 | -0.035 | -7.0% | $0.492 | $0.504 | $0.46 | 1,818,100 | |
| $0.50 | -0.02 | -3.8% | $0.527 | $0.547 | $0.50 | 1,744,400 | |
| $0.52 | +0.032 | +6.6% | $0.486 | $0.523 | $0.483 | 1,987,500 |
- Ticker
- NASDAQ:CNTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
Latest deck · Nov 10, 2026
Investor Presentation (November 2026)
Investor deck · 37 slides
Latest news
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
Nov 10, 2026
Closed $0.216 (+15.6%) on Nov 11, 2026
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
Sep 9, 2026
Closed $0.37 (-1.6%) on Sep 9, 2026
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Aug 5, 2026
Closed $0.504 (-27.3%) on Aug 6, 2026
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Jul 6, 2026
Closed $0.70 (+9.7%) on Jul 7, 2026
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
Jun 15, 2026
Closed $0.679 (-51.2%) on Jun 15, 2026
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
May 27, 2026
Closed $2.98 (+13.3%) on May 27, 2026
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 18, 2026
Closed $2.15 (-0.5%) on May 18, 2026
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
May 6, 2026
Closed $2.33 (-3.3%) on May 7, 2026
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Apr 2, 2026
Closed $2.72 (+2.6%) on Apr 2, 2026
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Mar 23, 2026
Closed $3.02 (+4.9%) on Mar 23, 2026
Context Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 73 in all · newest Nov 10, 2026 · oldest 2021
- Decks
- 26 decks · latest Nov 10, 2026
Where Context Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CNTX · Home listing · This page | NASDAQ | United States | USD |
| gettex:6K9 | gettex | Germany | EUR |
| LS Exchange:A3CWBU | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3CWBU | Lang & Schwarz | Germany | EUR |
| BOATS:CNTX | BOATS | United States | USD |
| Frankfurt:6K9 | Frankfurt | Germany | EUR |
| Munich:6K9 | Munich | Germany | EUR |
| Stuttgart:6K9 | Stuttgart | Germany | EUR |
| Tradegate:6K9 | Tradegate | Germany | EUR |
Valuation
Price/book 0.5× against a median of 0.8×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$19.50M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.99
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Context Therapeutics Inc. · NASDAQ:CNTX | US$14.70M | −US$19.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.99 |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| NewcelX Ltd. · NASDAQ:NCEL | US$14.67M | US$14.35M | n/a | n/a | n/a | 2.4× | n/a | 0.1× | 0.89 |
| Hepion Pharmaceuticals, Inc. · OTC:HEPA | US$14.63M | US$10.37M | n/a | n/a | n/a | n/a | n/a | n/a | -1.02 |
| Vectorite Biomedical, Inc. · TPEX:4170 | US$14.21M | US$9.16M | 4.9× | 4.9× | n/a | 0.9× | 156.6% | 0.0× | n/a |
| Estrella Immunopharma, Inc. · NASDAQ:ESLA | US$14.11M | US$14.01M | n/a | n/a | n/a | n/a | n/a | n/a | 1.31 |
| Citius Pharmaceuticals, Inc. · NASDAQ:CTXR | US$13.96M | −US$3.05M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.71 |
| TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549 | US$13.69M | US$11.86M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| Median of the others | US$14.42M | US$10.94M | 4.9× | 3.8× | 0.8× | 19.6% | 0.0× | 1.10 |
Forecasts
6 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.14 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.46 · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Martin Lehr | Chief Executive Officer |
| Jennifer Minai-Azary | Chief Financial Officer |
| Alex Levit | Chief Legal Officer |
| Christopher Beck | SVP of Operations |
| Jennifer Dashnau | SVP Technical Operations |
| Curtis Reinard | Director, Clinical Operations |
| Gregory Moylan | Executive Director, External Manufacturing |
| Indu Ramachandran | Executive Director, Translational Medicine |
| Karen Chagin | Chief Medical Officer |
| Michael Girouard | Executive Director, Quality |
Board
| Director | Role |
|---|---|
| Andy Pasternak | Chairman, Independent Director |
| Gregory Moylan | Executive Director, External Manufacturing |
| Indu Ramachandran | Executive Director, Translational Medicine |
| Jennifer Evans Stacey | Independent Director |
| Karen Smith | Independent Director |
| Linda West | Independent Director |
| Luke Walker | Independent Director |
| Martin Lehr | Chief Executive Officer |
| Michael Girouard | Executive Director, Quality |
| Philip Kantoff | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +15.6% |
| Q2 2026 | Aug 5, 2026 · After close | −27.3% |
| Q1 2026 | May 6, 2026 · After close | −3.3% |
| Q4 2025 | Mar 25, 2026 | −20.1% |
| Q3 2025 | Nov 5, 2025 · After close | −5.3% |
| Q2 2025 | Aug 6, 2025 · After close | 0.0% |
| Q1 2025 | May 7, 2025 · After close | +0.0% |
| Q4 2024 | Mar 20, 2025 | −5.8% |
| Q3 2024 | Nov 6, 2024 · After close | −5.9% |
| Q2 2024 | Aug 7, 2024 · After close | +2.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +1.1% |
| Q4 2023 | Mar 21, 2024 · Before open | −7.0% |
| Q3 2023 | Nov 9, 2023 · After close | −2.0% |
| Q2 2023 | Aug 9, 2023 · After close | +10.6% |
| Q1 2023 | May 10, 2023 · After close | −6.4% |
| Q4 2022 | Mar 22, 2023 | −7.6% |
| Q3 2022 | Nov 9, 2022 · After close | +0.9% |
| Q2 2022 | Aug 11, 2022 · After close | −3.5% |
| Q1 2022 | May 11, 2022 · After close | +7.0% |
| Q4 2021 | Mar 23, 2022 | −1.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 37 slides | Nov 10, 2026 |
| Investor Presentation (August 2026) | Investor deck | 37 slides | August 2026 |
| Technical Presentation (June 2026) | Technical | 31 slides | Jun 15, 2026 |
| Investor Presentation (June 2026) | Investor deck | 44 slides | Jun 15, 2026 |
| Investor Presentation (March 2026) | Investor deck | 35 slides | Mar 23, 2026 |
| Investor Presentation (January 2026) | Investor deck | 40 slides | Jan 8, 2026 |
| Investor Presentation (November 2025) | Investor deck | 40 slides | Nov 5, 2025 |
| Investor Presentation (June 2025) | Investor deck | 39 slides | Jun 2, 2025 |
| Investor Presentation (December 2024) | Investor deck | 43 slides | Dec 2, 2024 |
| Investor Presentation (September 2024) | Investor deck | 42 slides | Sep 23, 2024 |
All 26 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2024) | Investor deck | 29 slides | Jul 10, 2024 |
| Investor Presentation (May 2024) | Investor deck | 24 slides | May 2, 2024 |
| Investor Presentation (March 2024) | Investor deck | 23 slides | Mar 6, 2024 |
| Investor Presentation (October 2023) | Investor deck | 31 slides | Oct 31, 2023 |
| Investor Presentation (August 2023) | Investor deck | 26 slides | Aug 7, 2023 |
| Investor Presentation (March 2023) | Investor deck | 30 slides | Mar 22, 2023 |
| Investor Presentation (February 2023) | Investor deck | 40 slides | Feb 6, 2023 |
| Investor Presentation (January 2023) | Investor deck | 39 slides | Jan 4, 2023 |
| Technical Presentation (December 2022) | Technical | 41 slides | Dec 1, 2022 |
| Investor Presentation (November 2022) | Investor deck | 28 slides | Nov 9, 2022 |
| Investor Presentation (September 2022) | Investor deck | 25 slides | Sep 27, 2022 |
| Investor Presentation (August 2022) | Investor deck | 26 slides | Aug 2, 2022 |
| Investor Presentation (January 2022) | Investor deck | 22 slides | Jan 10, 2022 |
| IPO Roadshow (October 2021) | IPO roadshow | 45 slides | Oct 18, 2021 |
| IPO Roadshow (July 2021) | IPO roadshow | 41 slides | Jul 12, 2021 |
| IPO Roadshow (July 2021) | IPO roadshow | 42 slides | Jul 2, 2021 |
IPO
Priced at US$5.00 a share on Oct 19, 2021.
- Price
- US$5.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$25 million
- Underwriters' option
- Up to 750,000 more shares
- Underwriter
- ThinkEquity
- Shares delivered
- On or about Oct 22, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 22, 2021 |
| Filed publicly | May 27, 2021 |
| Amended 7 times | Newest Oct 18, 2021 |
| Shares registered with an exchange | Jul 23, 2021 |
| Declared effective by the SEC | Oct 19, 2021 |
| Final prospectus, with the price | Oct 20, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 20, 2021 |
| EFFECT · Notice that a registration is effective | Oct 19, 2021 |
| FWP · Free writing prospectus | Oct 18, 2021 |
| S-1/A · Registration statement, amended | Oct 18, 2021 |
| CORRESP · Letter to the SEC | Oct 15, 2021 |
| CORRESP · Letter to the SEC | Oct 15, 2021 |
| FWP · Free writing prospectus | Sep 29, 2021 |
| S-1/A · Registration statement, amended | Sep 29, 2021 |
| CORRESP · Letter to the SEC | Sep 24, 2021 |
| FWP · Free writing prospectus | Sep 24, 2021 |
All 38 filings
Open IPO · From the cover of the final prospectus (424B4) filed Oct 20, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 124.7K | 52.7K | 12.0K | 9.27K | 0 | 0 | |||
| Gross profit | -124.7K | -52.7K | -12.0K | -9.27K | 0 | 0 | |||
| Research and development | 31.9M | 22.7M | 17.8M | 7.09M | 3.81M | 1.64M | 2.41M | 17.6M | 27.8M |
| Selling, general and administrative | 7.85M | 7.22M | 7.29M | 7.79M | 3.63M | 930.7K | 2.97M | 24.0M | 33.2M |
| Operating income | -39.7M | -29.9M | -25.1M | -15.4M | -10.5M | -2.57M | -5.38M | -24.1M | -33.2M |
| Depreciation and amortization | 16.3K | 10.9K | 12.0K | 9.27K | 0 | 2.57K | 5.38K | 21.0K | 36.0K |
| EBITDA | -39.7M | -29.9M | -25.1M | -15.4M | -10.5M | -2.57M | -5.37M | -24.0M | -33.2M |
| Interest expense | 547.3K | 64.2K | 661.2K | 1.10M | 0 | 0 | |||
| Income before tax | -36.1M | -26.7M | -24.0M | -14.8M | -10.5M | 6.64M | -6.38M | -25.1M | -37.7M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 1.10M | -441.0K | 0 |
| Net income | -36.1M | -26.7M | -24.0M | -14.8M | -10.5M | 6.64M | -7.48M | -24.6M | -37.7M |
| Earnings per share, basic | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 | 3.07 | -0.68 | ||
| Earnings per share, diluted | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 | -3.96 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 66.0M | 94.4M | 14.4M | 35.5M | 49.6M | 290.7K | 226.6K | 60.7M | 16.2M |
| Current assets | 68.4M | 97.9M | 16.0M | 37.9M | 51.3M | 299.3K | 239.6K | 61.3M | 17.1M |
| Property, plant and equipment | 29.7K | 12.0K | 15.5K | 27.6K | 0 | 29.0K | 60.0K | ||
| Goodwill | 1.40M | 1.40M | |||||||
| Total assets | 68.5M | 98.1M | 16.1M | 38.0M | 51.3M | 467.3K | 273.5K | 68.3M | 24.0M |
| Accounts payable | 2.53M | 1.45M | 2.38M | 936.3K | 1.83M | 2.71M | 2.07M | 2.02M | 1.69M |
| Current liabilities | 8.02M | 2.75M | 4.19M | 3.21M | 3.03M | 9.55M | 24.1M | 4.97M | 4.91M |
| Long-term debt | 69.0K | 390.0K | 1.96M | ||||||
| Total debt | 112.1K | 219.4K | 55.1K | 5.95M | 21.8M | ||||
| Total liabilities | 8.02M | 2.86M | 4.19M | 3.21M | 3.03M | 9.62M | 24.2M | 9.38M | 10.9M |
| Shareholders' equity | 60.5M | 95.3M | 11.9M | 34.8M | 48.3M | -16.9M | -24.0M | 59.0M | 13.1M |
| Shares outstanding | 91.9M | 89.7M | 16.0M | 16.0M | 16.0M | 331.8K | 11.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -26.4M | -14.6M | -21.0M | -13.5M | -8.80M | -1.03M | -2.84M | -22.3M | -30.6M |
| Capital spending | -33.9K | -7.32K | 0 | -36.8K | 0 | 0 | 0 | -28.0K | -28.0K |
| Free cash flow | -26.4M | -14.6M | -21.0M | -13.6M | -8.80M | -1.03M | -2.84M | -22.4M | -30.6M |
| Cash from investing | -2.03M | -14.8M | 0 | -536.8K | -250.0K | 0 | -250.0K | -28.0K | -28.0K |
| Cash from financing | -15.3K | 109.3M | 0 | -102.1K | 58.4M | 1.15M | 1.96M | 66.8M | 44.2M |
| Change in cash | -28.4M | 80.0M | -21.0M | -14.2M | 49.3M | 114.4K | -878.7K | 44.4M | 13.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 5, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 8-K · Current report | May 18, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 23, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 23, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 23, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2026 | Current report | SEC |
| 8-K · Current report | Feb 27, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 3, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 5, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 24, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 24, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 20, 2025 | Current report | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 15, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 28, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 27, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 23, 2024 | Current report | SEC |
| 8-K · Current report | Dec 2, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 2, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 15, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Nov 12, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 12, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Sep 23, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 17, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 4, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jul 24, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 24, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 12, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 10, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| SC 13G · Big-stake notice | Jun 5, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jun 3, 2024 | Other filings | SEC |
| 424B3 · Prospectus | May 31, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 29, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 29, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | May 24, 2024 | Big-stake notice | SEC |
| S-3 · Registration statement | May 24, 2024 | Offer document | SEC |
| D | May 16, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | May 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | May 10, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2024 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 22, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 21, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Current report | SEC |
| 8-K · Current report | Mar 6, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 5, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2023 | Current report | SEC |
| 8-K · Current report | Jun 20, 2023 | Current report | SEC |
| 8-K · Current report | Jun 2, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 10, 2023 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 6, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 6, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 27, 2023 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 22, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 22, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 22, 2023 | Results | SEC |
| 4 · Change in ownership | Feb 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 6, 2023 | Current report | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 27, 2023 | Current report | SEC |
| 4 · Change in ownership | Jan 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 10, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 9, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 4, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 19, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2022 | Insider trade | SEC |
| 8-K · Current report | Dec 8, 2022 | Current report | SEC |
| 8-K · Current report | Dec 1, 2022 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 17, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 14, 2022 | Other filings | SEC |
| 424B3 · Prospectus | Nov 14, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 14, 2022 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 14, 2022 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Nov 9, 2022 | Offer document | SEC |
| S-3 · Registration statement | Nov 9, 2022 | Offer document | SEC |
| 424B3 · Prospectus | Nov 9, 2022 | Offer document | SEC |
| 8-K · Current report | Nov 9, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Nov 9, 2022 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Oct 27, 2022 | Big-stake notice | SEC |
| 424B3 · Prospectus | Sep 27, 2022 | Offer document | SEC |
This page holds 200 of 309 filings. Open Filings
Cap table
Built by 6ix from Context Therapeutics Inc.’s releases · as of Nov 6, 2026
- Common shares
- 91,879,177
- Fully diluted
- 91,879,177
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 91,879,177 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 91,879,177 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Karen Smith Other companies: Skye Bioscience, Inc. (Director · Since at least Jul 2, 2024); Sangamo Therapeutics, Inc. (Director · Since at least Jun 26, 2018); Aurinia Pharmaceuticals Inc (Director · Aug 18, 2023 – Nov 21, 2024 · Past); Quince Therapeutics, Inc. (Chief Medical Officer · May 19, 2022 – Feb 1, 2023 · Past); Tourmaline Bio Inc. (Director · May 16, 2022 – Jun 13, 2023 · Past); Emergent BioSolutions Inc. (EVP, Chief Medical Officer · May 21, 2020 – May 7, 2021 · Past); Antares Pharma Inc (Director · Mar 1, 2019 – May 24, 2022 · Past); Acceleron Pharma Inc (Director · Nov 15, 2017 – Nov 19, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Jul 15, 2017 – Feb 13, 2018 · Past); Jazz Pharmaceuticals plc (EVP, R&D and CMO · Apr 13, 2015 – Mar 5, 2018 · Past) | Independent Director · Since at least Sep 4, 2024 |
| Luke Walker Other companies: Zentalis Pharmaceuticals, Inc. (Director · Since at least May 24, 2024); Harpoon Therapeutics Inc (Chief Medical Officer · Oct 3, 2022 – Mar 11, 2024 · Past) | Director · Since at least Sep 4, 2024 |
| Linda West Other companies: Galera Therapeutics, Inc. (Director · Mar 31, 2020 – Jul 1, 2023 · Past) | Independent Director · Since at least Oct 19, 2021 |
| Philip W Kantoff Other companies: ESSA Pharma Inc (Director · Sep 13, 2022 – Mar 25, 2024 · Past) | Director · Since at least Oct 19, 2021 |
| Alex Levit | Chief Legal Officer · Since at least Nov 5, 2026 |
| Andy Pasternak | Chairman, Independent Director · Since at least Jan 13, 2025 |
| Christopher Beck | SVP of Operations · Since at least Nov 5, 2026 |
| Curtis Reinard | Director, Clinical Operations · Since at least Nov 5, 2026 |
| Erin Zebrowski | Director, Clinical Sciences · Nov 4, 2026 – Nov 4, 2026 · Past |
| Gregory Moylan | Executive Director, External Manufacturing · Since at least Nov 5, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Indu Ramachandran | Executive Director, Translational Medicine · Since at least Nov 5, 2026 |
| Jennifer Dashnau | SVP Technical Operations · Since at least Nov 5, 2026 |
| Jennifer Evans Stacey | Independent Director · Since at least Nov 5, 2026 |
| Jennifer Minai-Azary | Chief Financial Officer · Since at least Sep 9, 2026 |
| Karen Chagin | Chief Medical Officer · Since at least Jun 9, 2025 |
| Martin Lehr | Chief Executive Officer · Since at least Aug 19, 2022 |
| Mary Sphar | Executive Assistant & Office Manager · Nov 4, 2026 – Nov 4, 2026 · Past |
| Michael Girouard | Executive Director, Quality · Since at least Nov 5, 2026 |
| Philip Kantoff | Independent Director · Since at least Nov 4, 2026 |
| Ullmann Claudio Dansky | Chief Medical Officer · Aug 1, 2024 – Feb 13, 2025 · Past |
| William F Rencher | Head of CMC and Regulatory · Oct 19, 2021 – Oct 19, 2021 · Past |
Log in to ask 6ix AI your own questions about Context Therapeutics Inc.